文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Advances in protein subunit vaccines against H1N1/09 influenza.

作者信息

Zhang Yu, Gao Jingyao, Xu Wenqi, Huo Xingyu, Wang Jingyan, Xu Yirui, Ding Wenting, Guo Zeliang, Liu Rongzeng

机构信息

Department of Immunology, College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, China.

Department of Medical Imaging, School of Medicine, Zhoukou Vocational and Technical College, Zhoukou, China.

出版信息

Front Immunol. 2024 Nov 22;15:1499754. doi: 10.3389/fimmu.2024.1499754. eCollection 2024.


DOI:10.3389/fimmu.2024.1499754
PMID:39650643
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11621219/
Abstract

The A/H1N1pdm09 influenza virus, which caused the 2009 pandemic, has since become a recurring strain in seasonal influenza outbreaks. Given the ongoing threat of influenza, protein subunit vaccines have garnered significant attention for their safety and effectiveness. This review seeks to highlight the latest developments in protein subunit vaccines that specifically target the A/H1N1pdm09 virus. It will also examine the structure and replication cycle of influenza A viruses and compare different types of influenza vaccines. Additionally, the review will address key aspects of H1N1 protein subunit vaccine development, such as antigen selection, protein expression systems, and the use of adjuvants. The role of animal models in evaluating these vaccines will also be discussed. Despite challenges like antigenic variability and the complexities of vaccine production and distribution, protein subunit vaccines remain a promising option for future influenza prevention efforts.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/11621219/8ae51a832311/fimmu-15-1499754-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/11621219/8fde793deae0/fimmu-15-1499754-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/11621219/489ce0923e07/fimmu-15-1499754-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/11621219/902dbd7f80a8/fimmu-15-1499754-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/11621219/af29331042ee/fimmu-15-1499754-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/11621219/8ae51a832311/fimmu-15-1499754-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/11621219/8fde793deae0/fimmu-15-1499754-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/11621219/489ce0923e07/fimmu-15-1499754-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/11621219/902dbd7f80a8/fimmu-15-1499754-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/11621219/af29331042ee/fimmu-15-1499754-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b32/11621219/8ae51a832311/fimmu-15-1499754-g005.jpg

相似文献

[1]
Advances in protein subunit vaccines against H1N1/09 influenza.

Front Immunol. 2024-11-22

[2]
Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly.

Clin Vaccine Immunol. 2014-7

[3]
A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses.

Influenza Other Respir Viruses. 2008-11

[4]
[Increasing the immunogenicity of inactivated chitosan adjuvanted vaccine from A/California/7/09 (H1N1) strain and analyzing the antigenic specificity of this influenza virus strain].

Vopr Virusol. 2012

[5]
Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial.

Lancet Infect Dis. 2010-12-16

[6]
Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza.

Hum Vaccin. 2011

[7]
Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.

J Prev Med Hyg. 2009-6

[8]
New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain.

Vaccine. 2013-4-17

[9]
Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: Blind, randomized, and placebo-controlled trial.

J Med Virol. 2017-9-25

[10]
Lipid nanoparticle-encapsulated DNA vaccine confers protection against swine and human-origin H1N1 influenza viruses.

mSphere. 2024-8-28

引用本文的文献

[1]
Evaluation of the multivalent immune protective effects of the outer membrane protein VF17320, and its DNA and IgY antibody vaccines in fish.

Front Vet Sci. 2025-6-18

[2]
The Bioengineering of Insect Cell Lines for Biotherapeutics and Vaccine Production: An Updated Review.

Vaccines (Basel). 2025-5-23

[3]
Monitoring Immune Responses to Vaccination: A Focus on Single-Cell Analysis and Associated Challenges.

Vaccines (Basel). 2025-4-16

本文引用的文献

[1]
A comprehensive review on recent advancements in drug delivery via selenium nanoparticles.

J Drug Target. 2025-2

[2]
Self-assembling nanoparticle engineered from the ferritinophagy complex as a rabies virus vaccine candidate.

Nat Commun. 2024-10-4

[3]
Improvement strategies for transient gene expression in mammalian cells.

Appl Microbiol Biotechnol. 2024-10-4

[4]
Strategies for developing self-assembled nanoparticle vaccines against SARS-CoV-2 infection.

Front Immunol. 2024

[5]
Self-Assembled Ferritin Nanoparticles for Delivery of Antigens and Development of Vaccines: From Structure and Property to Applications.

Molecules. 2024-9-5

[6]
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 Influenza Season.

MMWR Recomm Rep. 2024-8-29

[7]
Advancements in Nanoparticle-Based Strategies for Enhanced Antibacterial Interventions.

Cell Biochem Biophys. 2024-12

[8]
Metallic nanomaterials - targeted drug delivery approaches for improved bioavailability, reduced side toxicity, and enhanced patient outcomes.

Rom J Morphol Embryol. 2024

[9]
Molecular Events in Immune Responses to Sublingual Influenza Vaccine with Hemagglutinin Antigen and Poly(I:C) Adjuvant in Nonhuman Primates, Cynomolgus Macaques.

Vaccines (Basel). 2024-6-8

[10]
Preparation and characterization of curdlan-chitosan conjugate nanoparticles as mucosal adjuvants for intranasal influenza H1N1 subunit vaccine.

Int J Biol Macromol. 2024-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索